Literature DB >> 7560201

Apocrine adenosis: a precursor of aggressive breast cancer?

C A Wells1, I L McGregor, C N Makunura, P Yeomans, J D Davies.   

Abstract

AIM: To investigate overexpression of c-erbB2, expression of the p53 protein product and proliferation rates in benign breast lesions with specific reference to apocrine adenosis.
METHODS: Twenty one cases of apocrine adenosis were stained with monoclonal antibodies to p185, the protein product of the c-erbB2 oncogene, the protein product of the p53 tumour suppressor gene and to the cell cycle related protein Ki67. Three cases were associated with concomitant ductal carcinoma in situ of large cell type and two were associated with invasive tubular or cribriform carcinoma.
RESULTS: Twelve (57.1%) cases showed membrane staining for c-erbB2 oncoprotein of apocrine cells within sclerosing adenosis and six (28.6%) had occasional p53 protein positive cells. One case not associated with carcinoma showed extensive staining of apocrine metaplasia outside the area of apocrine adenosis. The proliferation rate, as measured by Ki67 staining, was increased in some of the lesions and all lesions showed at least some of the cells to be in the cell cycle.
CONCLUSIONS: The expression of abnormal oncogene products and increased proliferation in some of these apocrine lesions questions the supposed degenerative nature of the atypia seen in such cases and suggests that there may be an association between these lesions and large cell ductal carcinoma in situ and hence invasive carcinoma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7560201      PMCID: PMC502801          DOI: 10.1136/jcp.48.8.737

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  22 in total

1.  Mutant p53--the commonest genetic abnormality in human cancer?

Authors:  A L Harris
Journal:  J Pathol       Date:  1990-09       Impact factor: 7.996

2.  Adenomyoepithelioma of the breast with a distinctive type of apocrine adenosis.

Authors:  V Eusebi; G P Casadei; G Bussolati; J G Azzopardi
Journal:  Histopathology       Date:  1987-03       Impact factor: 5.087

3.  c-erB-2 oncoprotein expression in malignant and nonmalignant breast tissue.

Authors:  A McCann; P A Johnston; P A Dervan; W J Gullick; D N Carney
Journal:  Ir J Med Sci       Date:  1989-06       Impact factor: 1.568

4.  Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer.

Authors:  B A Gusterson; L G Machin; W J Gullick; N M Gibbs; T J Powles; P Price; A McKinna; S Harrison
Journal:  Int J Cancer       Date:  1988-12-15       Impact factor: 7.396

5.  Ductal involvement by cells of atypical lobular hyperplasia in the breast: a long-term follow-up study of cancer risk.

Authors:  D L Page; W D Dupont; L W Rogers
Journal:  Hum Pathol       Date:  1988-02       Impact factor: 3.466

6.  Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast.

Authors:  R F Lodato; H C Maguire; M I Greene; D B Weiner; V A LiVolsi
Journal:  Mod Pathol       Date:  1990-07       Impact factor: 7.842

7.  Invasive breast cancer risk in women with sclerosing adenosis.

Authors:  R A Jensen; D L Page; W D Dupont; L W Rogers
Journal:  Cancer       Date:  1989-11-15       Impact factor: 6.860

8.  A comparison of the results of long-term follow-up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast.

Authors:  F A Tavassoli; H J Norris
Journal:  Cancer       Date:  1990-02-01       Impact factor: 6.860

9.  Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ.

Authors:  J Bartkova; D M Barnes; R R Millis; W J Gullick
Journal:  Hum Pathol       Date:  1990-11       Impact factor: 3.466

10.  c-erbB-2 expression in benign and malignant breast disease.

Authors:  B A Gusterson; L G Machin; W J Gullick; N M Gibbs; T J Powles; C Elliott; S Ashley; P Monaghan; S Harrison
Journal:  Br J Cancer       Date:  1988-10       Impact factor: 7.640

View more
  10 in total

Review 1.  The enigmatic nature of apocrine breast lesions.

Authors:  P Zagorianakou; N Zagorianakou; D Stefanou; G Makrydimas; N J Agnantis
Journal:  Virchows Arch       Date:  2006-03-29       Impact factor: 4.064

Review 2.  Genomic Changes in Normal Breast Tissue in Women at Normal Risk or at High Risk for Breast Cancer.

Authors:  David N Danforth
Journal:  Breast Cancer (Auckl)       Date:  2016-08-17

3.  Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast.

Authors:  C Jones; S Damiani; D Wells; R Chaggar; S R Lakhani; V Eusebi
Journal:  Am J Pathol       Date:  2001-01       Impact factor: 4.307

4.  Immunohistochemical localisation of androgen receptor in apocrine metaplasia and apocrine adenosis of the breast: relation to oestrogen and progesterone receptors.

Authors:  A G Selim; C A Wells
Journal:  J Clin Pathol       Date:  1999-11       Impact factor: 3.411

Review 5.  Salivary gland-like tumours of the breast: surgical and molecular pathology.

Authors:  M Pia-Foschini; J S Reis-Filho; V Eusebi; S R Lakhani
Journal:  J Clin Pathol       Date:  2003-07       Impact factor: 3.411

6.  A functional and regulatory network associated with PIP expression in human breast cancer.

Authors:  Marie-Anne Debily; Sandrine El Marhomy; Virginie Boulanger; Eric Eveno; Régine Mariage-Samson; Alessandra Camarca; Charles Auffray; Dominique Piatier-Tonneau; Sandrine Imbeaud
Journal:  PLoS One       Date:  2009-03-05       Impact factor: 3.240

7.  Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia.

Authors:  Julio E Celis; José M A Moreira; Irina Gromova; Teresa Cabezón; Pavel Gromov; Tao Shen; Vera Timmermans; Fritz Rank
Journal:  Mol Oncol       Date:  2007-03-14       Impact factor: 6.603

Review 8.  The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.

Authors:  Jaclyn A Freudenberg; Qiang Wang; Makoto Katsumata; Jeffrey Drebin; Izumi Nagatomo; Mark I Greene
Journal:  Exp Mol Pathol       Date:  2009-05-18       Impact factor: 3.362

9.  Expression of C-KIT, CD24, CD44s, and COX2 in benign and non-invasive apocrine lesions of the breast.

Authors:  Trine Tramm; Jee-Yeon Kim; Sebastian Leibl; Farid Moinfar; Fattaneh A Tavassoli
Journal:  Virchows Arch       Date:  2016-06-10       Impact factor: 4.064

10.  P53 Expression in benign Breast Disease Development: A Systematic Review.

Authors:  Rafaela Soares Senra da Costa; Ilce Ferreira Da Silva
Journal:  Asian Pac J Cancer Prev       Date:  2020-09-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.